Kinoxis team.We recently announced Kinoxis Therapeutics Pty Ltd $14.5M Series B and our participation in this round. The funds raised will advance their lead candidate (KNX100) into Phase 2 clinical trials targeting agitation and aggression…
Harikesh Pushpapathan
https://stoicvc.com.au/wp-content/uploads/2024/09/11lSOK0WxCkC78BI-uCfsaw.jpeg415739Harikesh Pushpapathanhttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngHarikesh Pushpapathan2024-09-01 13:20:232024-09-06 11:05:09Why we doubled down on Kinoxis.
